{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:08:00Z","timestamp":1791176880037,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"44","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,5]],"date-time":"2014-08-05T00:00:00Z","timestamp":1407196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["CRN-83320"],"award-info":[{"award-number":["CRN-83320"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003267","name":"Qu\u00e9bec Ministry of Health and Social Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003267","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.vaccine.2014.07.099","type":"journal-article","created":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T15:49:07Z","timestamp":1407858547000},"page":"5845-5853","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: A transmission-dynamic modelling study"],"prefix":"10.1016","volume":"32","author":[{"given":"Jean-Fran\u00e7ois","family":"Laprise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Drolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Boily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Sauvageau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo L.","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lemieux-Mellouki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal\u00eda","family":"Malag\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Brisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 5","key":"10.1016\/j.vaccine.2014.07.099_bib0005","doi-asserted-by":"crossref","first-page":"F139","DOI":"10.1016\/j.vaccine.2012.05.039","article-title":"Human papillomavirus vaccine introduction \u2013 the first five years","volume":"30","author":"Markowitz","year":"2012","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2014.07.099_bib0010","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Munoz","year":"2003","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2014.07.099_bib0015","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/ijc.24116","article-title":"Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis","volume":"124","author":"De Vuyst","year":"2009","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.vaccine.2014.07.099_bib0020","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10552-008-9276-9","article-title":"Systematic review of human papillomavirus prevalence in invasive penile cancer","volume":"20","author":"Backes","year":"2009","journal-title":"Cancer Causes Control"},{"issue":"2","key":"10.1016\/j.vaccine.2014.07.099_bib0025","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/1055-9965.EPI-04-0551","article-title":"Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review","volume":"14","author":"Kreimer","year":"2005","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"6","key":"10.1016\/j.vaccine.2014.07.099_bib0030","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/597071","article-title":"Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine","volume":"199","author":"Garland","year":"2009","journal-title":"J Infect Dis"},{"issue":"19","key":"10.1016\/j.vaccine.2014.07.099_bib0035","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.vaccine.2014.07.099_bib0040","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/jnci\/djs395","article-title":"Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis","volume":"104","author":"Van de Velde","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2014.07.099_bib0045","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000214924","article-title":"Economic evaluation of human papillomavirus vaccination in developed countries","volume":"12","author":"Brisson","year":"2009","journal-title":"Public Health Genomics"},{"issue":"Suppl. 10","key":"10.1016\/j.vaccine.2014.07.099_bib0050","doi-asserted-by":"crossref","first-page":"K76","DOI":"10.1016\/j.vaccine.2008.06.009","article-title":"Modeling cervical cancer prevention in developed countries","volume":"26","author":"Kim","year":"2008","journal-title":"Vaccine"},{"issue":"Suppl. 5","key":"10.1016\/j.vaccine.2014.07.099_bib0055","doi-asserted-by":"crossref","first-page":"F157","DOI":"10.1016\/j.vaccine.2012.06.091","article-title":"Modeling preventative strategies against human papillomavirus-related disease in developed countries","volume":"30","author":"Canfell","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.07.099_bib0060","series-title":"Immunization in British Colombia","author":"BC Center for Disease Control","year":"2008"},{"issue":"19","key":"10.1016\/j.vaccine.2014.07.099_bib0065","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"10.1016\/j.vaccine.2014.07.099_bib0070","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.vaccine.2014.07.099_bib0075","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1001\/jama.2013.4147","article-title":"HPV vaccination: too soon for 2 doses?","volume":"309","author":"Kahn","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.vaccine.2014.07.099_bib0080","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2165\/11539960-000000000-00000","article-title":"Modelling the epidemiology of infectious diseases for decision analysis: a primer","volume":"29","author":"Jit","year":"2011","journal-title":"Pharmacoeconomics"},{"issue":"33","key":"10.1016\/j.vaccine.2014.07.099_bib0090","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1016\/j.vaccine.2010.05.056","article-title":"Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis","volume":"28","author":"Van de Velde","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.07.099_bib0095","article-title":"HPV-advise: technical appendix","author":"Brisson","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.vaccine.2014.07.099_bib0115","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1177\/0272989X12454578","article-title":"Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5","volume":"32","author":"Pitman","year":"2012","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.vaccine.2014.07.099_bib0120","series-title":"Investing in health for economic development. Report of the Commission on Macroeconomics and Health, Geneva, Switzerland","author":"WHO","year":"2001"},{"key":"10.1016\/j.vaccine.2014.07.099_bib0125","series-title":"WHO-CHOICE. World Health Organization statistical information system: choosing interventions that are cost effective","author":"WHO","year":"2006"},{"key":"10.1016\/j.vaccine.2014.07.099_bib0130","series-title":"HPV vaccination programme: HPV annual survey 2011\u20132012","author":"Department of Health UK, Public Health England","year":"2012"},{"key":"10.1016\/j.vaccine.2014.07.099_bib0135","series-title":"Immunise Australia Program: human papillomavirus (HPV)","author":"Department of Health Australian Government","year":"2013"},{"issue":"3","key":"10.1016\/j.vaccine.2014.07.099_bib0140","first-page":"1","article-title":"Vigie \u2013 Interventions: Couverture vaccinale en milieu scolaire","volume":"5","author":"Minist\u00e8re de la Sant\u00e9 et des Services Sociaux du Qu\u00e9bec (MSSS)","year":"2010","journal-title":"Flash Vigie: Bull qu\u00e9 vigie d\u2019interv mal infect"},{"issue":"10","key":"10.1016\/j.vaccine.2014.07.099_bib0145","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/pon.2003","article-title":"The psychosocial impact of an abnormal cervical smear result","volume":"21","author":"Drolet","year":"2012","journal-title":"Psychooncology"},{"issue":"10","key":"10.1016\/j.vaccine.2014.07.099_bib0150","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/OLQ.0b013e3182215512","article-title":"The impact of anogenital warts on health-related quality of life: a 6-month prospective study","volume":"38","author":"Drolet","year":"2011","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2014.07.099_bib0155","series-title":"Statistics Canada Canadian Community Health Survey (CCHS \u2013 Cycle 3.1)","year":"2005"},{"key":"10.1016\/j.vaccine.2014.07.099_bib0160","series-title":"Epidemiology of cervical abnormalities and utilization of related health care resources","author":"Demers","year":"2009"},{"issue":"12","key":"10.1016\/j.vaccine.2014.07.099_bib0165","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1002\/ijc.23459","article-title":"Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia","volume":"122","author":"Ades","year":"2008","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.vaccine.2014.07.099_bib0170","first-page":"485","article-title":"The natural history of type-specific human papillomavirus infections in female university students","volume":"12","author":"Richardson","year":"2003","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"3","key":"10.1016\/j.vaccine.2014.07.099_bib0175","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ijc.21897","article-title":"Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST)","volume":"119","author":"Mayrand","year":"2006","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.vaccine.2014.07.099_bib0180","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/jmv.22081","article-title":"Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada","volume":"83","author":"Coutlee","year":"2011","journal-title":"J Med Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2014.07.099_bib0185","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ijc.25396","article-title":"Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication","volume":"128","author":"Li","year":"2011","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.vaccine.2014.07.099_bib0190","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1525-1438.2001.011001024.x","article-title":"Cervical cancer in Canada: changing patterns in incidence and mortality","volume":"11","author":"Liu","year":"2001","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.vaccine.2014.07.099_bib0195","unstructured":"Public Health Agency of Canada. Cancer surveillance on-line. Available from: http:\/\/dsol-smed.phac-aspc.gc.ca\/dsol-smed\/cancer\/index-eng.php [accessed January 2011]."},{"key":"10.1016\/j.vaccine.2014.07.099_bib0200","series-title":"Cervical cancer screening program. 2009 annual report, Vancouver, BC","author":"BC Cancer Agency","year":"2009"},{"issue":"6","key":"10.1016\/j.vaccine.2014.07.099_bib0205","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/OLQ.0b013e318198de8c","article-title":"Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada","volume":"36","author":"Kliewer","year":"2009","journal-title":"Sex Transm Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2014.07.099_bib0210","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","article-title":"Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis","volume":"12","author":"Malagon","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2014.07.099_bib0215","series-title":"Abstract presented at the 27th International Papillomavirus Conference and Clinical Workshop","first-page":"17","article-title":"Sustained immunogenicity and efficacy of the HPV-16\/18 vaccine in women aged 15\u201325 years: follow-up to 9.4 years","author":"Naud","year":"2011"},{"issue":"6","key":"10.1016\/j.vaccine.2014.07.099_bib0220","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00005650-199806000-00002","article-title":"Toward consistency in cost\u2013utility analyses: using national measures to create condition-specific values","volume":"36","author":"Gold","year":"1998","journal-title":"Med Care"},{"key":"10.1016\/j.vaccine.2014.07.099_bib0225","series-title":"Vaccines for the 21st century: a tool for decision making","author":"Institute of Medicine of the National Academies","year":"1999"},{"issue":"10","key":"10.1016\/j.vaccine.2014.07.099_bib0230","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.ijom.2006.07.017","article-title":"Patients\u2019 perceived health status following primary surgery for oral and oropharyngeal cancer","volume":"35","author":"Rogers","year":"2006","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"29","key":"10.1016\/j.vaccine.2014.07.099_bib0235","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1016\/j.vaccine.2007.04.086","article-title":"The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada","volume":"25","author":"Brisson","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.07.099_bib0240","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/1471-2458-9-401","article-title":"A cost\u2013utility analysis of cervical cancer vaccination in preadolescent Canadian females","volume":"9","author":"Anonychuk","year":"2009","journal-title":"BMC Public Health"},{"issue":"3","key":"10.1016\/j.vaccine.2014.07.099_bib0245","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/BF03404377","article-title":"Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Quebec: Canada","volume":"101","author":"Vijayaraghavan","year":"2010","journal-title":"Can J Public Health"},{"key":"10.1016\/j.vaccine.2014.07.099_bib0250","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1741-7015-7-69","article-title":"Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis","volume":"7","author":"Kulasingam","year":"2009","journal-title":"BMC Med"},{"issue":"2","key":"10.1016\/j.vaccine.2014.07.099_bib0255","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/sti.2008.030999","article-title":"Epidemiology and costs associated with genital warts in Canada","volume":"85","author":"Marra","year":"2009","journal-title":"Sex Transm Infect"},{"issue":"3","key":"10.1016\/j.vaccine.2014.07.099_bib0260","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/01.LGT.0000171665.63976.B2","article-title":"Costs of colposcopy services and their impact on the incidence and mortality rate of cervical cancer in Canada","volume":"9","author":"Benedet","year":"2005","journal-title":"J Low Genit Tract Dis"},{"issue":"46","key":"10.1016\/j.vaccine.2014.07.099_bib0265","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1016\/j.vaccine.2011.07.096","article-title":"The cost-effectiveness of male HPV vaccination in the United States","volume":"29","author":"Chesson","year":"2011","journal-title":"Vaccine"},{"issue":"42","key":"10.1016\/j.vaccine.2014.07.099_bib0270","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1016\/j.vaccine.2010.08.030","article-title":"Impact of vaccinating boys and men against HPV in the United States","volume":"28","author":"Elbasha","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.07.099_bib0275","doi-asserted-by":"crossref","first-page":"a769","DOI":"10.1136\/bmj.a769","article-title":"Economic evaluation of human papillomavirus vaccination in the United Kingdom","volume":"337","author":"Jit","year":"2008","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.vaccine.2014.07.099_bib0280","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S0266462310000085","article-title":"Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark","volume":"26","author":"Olsen","year":"2010","journal-title":"Int J Technol Assess Health Care"},{"issue":"11","key":"10.1016\/j.vaccine.2014.07.099_bib0285","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3201\/eid1011.040222","article-title":"Evaluating human papillomavirus vaccination programs","volume":"10","author":"Taira","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2014.07.099_bib0290","series-title":"La Vaccination contre les VPH au Qu\u00e9bec: Mise \u00e0 jour des connaissances et propositions du comit\u00e9 d\u2019experts. Direction des risques biologiques et de la sant\u00e9 au travail","author":"Comit\u00e9 sur l\u2019immunisation du Qu\u00e9bec (CIQ) et Comit\u00e9 scientifique ad hoc VPH","year":"2012"},{"key":"10.1016\/j.vaccine.2014.07.099_bib0295","doi-asserted-by":"crossref","first-page":"f2032","DOI":"10.1136\/bmj.f2032","article-title":"Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data","volume":"346","author":"Ali","year":"2013","journal-title":"BMJ"},{"issue":"4 Suppl.","key":"10.1016\/j.vaccine.2014.07.099_bib0300","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jadohealth.2010.01.010","article-title":"Human papillomavirus-related disease in men: not just a women's issue","volume":"46","author":"Palefsky","year":"2010","journal-title":"J Adolesc Health"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2014.07.099_bib0305","first-page":"S3.11","article-title":"Chapter 2: The burden of HPV-related cancers","volume":"24","author":"Parkin","year":"2006","journal-title":"Vaccine"},{"issue":"26","key":"10.1016\/j.vaccine.2014.07.099_bib0310","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1016\/j.vaccine.2014.03.098","article-title":"Two-dose strategies for human papillomavirus vaccination: how well do they need to protect?","volume":"32","author":"Jit","year":"2014","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2014.07.099_bib0315","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/sextrans-2011-050234","article-title":"The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme","volume":"87","author":"Read","year":"2011","journal-title":"Sex Transm Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2014.07.099_bib0320","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","article-title":"Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices \u2013 modeling studies","volume":"6","author":"Weinstein","year":"2003","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vaccine.2014.07.099_bib0325","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(10)70225-5","article-title":"Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data","volume":"11","author":"Donovan","year":"2011","journal-title":"Lancet Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14010810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14010810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T00:56:08Z","timestamp":1598144168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14010810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":61,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0264410X14010810"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.07.099","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: A transmission-dynamic modelling study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.07.099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}